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Abstract
O-GlcNAcylation (addition of N-acetyl-glucosamine on serine or threonine residues) is a post-translational
modification that regulates stability, activity or localization of cytosolic and nuclear proteins. O-linked N-
acetylgluocosmaine transferase (OGT) uses UDP-GlcNAc, produced in the hexosamine biosynthetic pathway to O-
GlcNacylate proteins. Removal of O-GlcNAc from proteins is catalyzed by the β-N-Acetylglucosaminidase (OGA).
Recent evidences suggest that O-GlcNAcylation may affect the growth of cancer cells. However, the consequences
of O-GlcNAcylation on anti-cancer therapy have not been evaluated. In this work, we studied the effects of O-
GlcNAcylation on tamoxifen-induced cell death in the breast cancer-derived MCF-7 cells. Treatments that increase
O-GlcNAcylation (PUGNAc and/or glucosoamine) protected MCF-7 cells from death induced by tamoxifen. In
contrast, inhibition of OGT expression by siRNA potentiated the effect of tamoxifen on cell death. Since the PI-3
kinase/Akt pathway is a major regulator of cell survival, we used BRET to evaluate the effect of PUGNAc
+glucosamine on PIP3 production. We observed that these treatments stimulated PIP3 production in MCF-7 cells.
This effect was associated with an increase in Akt phosphorylation. However, the PI-3 kinase inhibitor LY294002,
which abolished the effect of PUGNAc+glucosamine on Akt phosphorylation, did not impair the protective effects of
PUGNAc+glucosamine against tamoxifen-induced cell death. These results suggest that the protective effects of O-
GlcNAcylation are independent of the PI-3 kinase/Akt pathway. As tamoxifen sensitivity depends on the estrogen
receptor (ERα) expression level, we evaluated the effect of PUGNAc+glucosamine on the expression of this receptor.
We observed that O-GlcNAcylation-inducing treatment significantly reduced the expression of ERα mRNA and
protein, suggesting a potential mechanism for the decreased tamoxifen sensitivity induced by these treatments.
Therefore, our results suggest that inhibition of O-GlcNAcylation may constitute an interesting approach to improve
the sensitivity of breast cancer to anti-estrogen therapy.
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Introduction
Growth and proliferation of cancer cells tightly depend on
their nutritional environment, particularly on glucose availability,
which is necessary for increased biosynthesis of cellular
components associated with proliferation (e.g. membranes,
proteins and nucleic acids) [1]. Nutritional and metabolic
conditions are known to influence tumour development. Excess
food intake associated with modern lifestyle constitutes an
important cancer risk factor [2]. In animals, food restriction has
inhibitory effects on the growth of certain tumours [3], whereas
in diet-induced obesity models, overfeeding is associated with
accelerated development of tumours [4].
Nutritional conditions can modulate tumour development by
modifying insulin and IGF-1 concentrations, which affect
signalling pathways involved in cell growth, proliferation and
apoptosis. However, at the cellular level, glucose can also
directly regulate signalling pathways and multiple biological
processes through O-GlcNAc glycosylation (O-GlcNAcylation)
of cytosolic and nuclear proteins [5]. O-GlcNAcylation is a
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reversible post-translational modification, analogous to
phosphorylation, which controls protein localisation, stability or
activity according to the nutritional environment. It corresponds
to the addition of N-Acetylglucosamine (GlcNAc) on serine or
threonine residues. This reaction is catalysed by O-GlcNAc
transferase (OGT), which uses UDP-GlcNAc as a substrate
(Figure 1). UDP-GlcNAc, produced through the hexosamine
biosynthetic pathway (HBP), can be considered as a sensor for
the nutritional state of the cell, as it integrates glucose,
glutamine, fatty acids (acetyl), uridine and ATP metabolism
[5–9]. O-GlcNAc is rapidly removed from proteins by O-
GlcNAcase (OGA), permitting dynamic regulation of O-
GlcNAcylation levels in cells.
A growing amount of studies indicates that O-GlcNAcylation
constitutes an important regulator of cancer growth and
invasion. A number of transcription factors involved in the
control of cell proliferation or cell death can be regulated by O-
GlcNAc [10–15]. Moreover, increased protein O-GlcNAcylation
has been detected in cells derived from breast, lung, colon,
liver and prostate cancers. These modifications, often
associated with changes in OGT and/or OGA levels [16–18],
favour the growth and/or migration of tumour cells through
Figure 1.  The hexosamine biosynthetic pathway controls O-GlcNAc-modification of proteins.  Cytosolic and nuclear O-
GlcNAc glycosylation constitutes a dynamic process that regulates the activity, the localisation or the stability of the modified
proteins. O-GlcNAc glycosylation of proteins on serine and threonine residues depends on the flux of glucose through the
hexosamine biosynthetic pathway (HBP). A fraction (2 to 5%) of the glucose entering the cell is directed into this pathway for the
biosynthesis of UDP-GlcNAc. OGT uses UDP-GlcNAc as a substrate to add GlcNAc on serine or threonine residues, and its activity
is tightly dependent on the concentration of UDP-GlcNAc in the cell. These modifications can be reversed by O-GlcNAcase (OGA),
which removes the O-GlcNAc moiety from O-GlcNAc-modified proteins. Experimentally, the level of O-GlcNAc in proteins can be
increased by incubating cells with glucosamine (which bypasses allosteric inhibition of the rate limiting enzyme GFAT (Glutamine
Fructose 6-P amidotransferase)), or with PUGNAc (O-[2-acetamido-2-deoxy-D-glucopyranosylidene] amino-N-phenylcarbamate),
which inhibits deglycosylation by OGA.
doi: 10.1371/journal.pone.0069150.g001
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different mechanisms, including regulation of transcription
factors activity [19,20], E-cadherin [18,21], and MMP
metalloproteases [18,20].
Breast cancer is the most common cancer in women.
Endocrine therapies have permitted important progress for the
treatment of hormone-sensitive breast cancers. However, the
development of treatment resistance constitutes an important
limitation to these therapies. Thus, tamoxifen, a partial
antagonist of the estrogen receptor, has been largely used for
the treatment of estrogen receptor positive breast cancers, but
resistance to this drug often occurs [22]. The link between
nutritional conditions, obesity and breast cancer is well
established, particularly in menopausal women [23]. However,
few studies have evaluated the consequences of metabolic
manipulations on the efficiency of anti-cancer therapy. In this
work, we studied the effect of treatments that induce protein O-
GlcNAcylation on the sensitivity to tamoxifen, using the human
breast cancer derived, estrogen receptor positive MCF-7 cell
line.
Methods
Chemicals and antibodies
Glucosamine (GlcN) was from Sigma-Aldrich, O-(2-
acetamido-2-deoxy-D-glucopyranosylidene)-amino-N-
phenylcarbamate (PUGNAc) from Toronto Research
Chemicals Inc., and LY294002 from Cell Signaling Technology.
Anti-Akt, anti-Phospho-Akt and anti-phospho-Erk1/2 antibodies
were from Cell Signaling Technology, anti-ERα (60C) from
Millipore, anti-O-GlcNAc (CTD 110.6) from Covance, anti-
GAPDH from Life Technologies, anti-β-actin from Sigma, anti-
Erk2 (sc 154) and HRP-conjugated donkey anti-rabbit (sc
2305) from Santa Cruz, and HRP-conjugated goat anti-mouse
from Jackson ImmunoResearch laboratories.
Cell culture and transfection
MCF-7 cells were maintained in DMEM supplemented with
10% fetal bovine serum. Transfection of siRNA and cDNAs
were performed with Lipofectamine RNAi Max (Life
Technologies) and FuGene 6 (Promega), respectively. The
negative control siRNA was from Eurogentec (Seraing,
Belgium).
Uptiblue assay
Cells were plated in clear 96-well-plates at a density of 2000
cells/well. 24 h after plating, cell population density was
evaluated 2h30 after adding 10% Uptiblue reagent, by
measuring fluorescence (initial fluorescence) at 595 nm using
Typhoon 9400 imager (GE Healthcare). Cells were then
cultured for 24 or 48 h in fresh media containing the different
agents, and then the final fluorescence was measured. The cell
population growth in each well was expressed as the ratio of
the final fluorescence over the initial one in the same culture
well [24].
Apoptosis analysis
After treatment in 6-well-plates, cells were harvested by
trypsin digestion, washed in PBS and labelled with both
Annexin-V-FITC and propidium iodide using the Annexin-V
FLUOS kit (Roche Diagnostics) according to manufacturers’
instructions. Cells were analyzed by flow cytometry with the FC
500 cytometer (Beckman Coulter).
BRET experiments
Luc-Akt-PH and YFP-Mem cDNAs used for the study of PIP3
production have been previously described [25]. MCF-7 cells
were transfected with 0.7 µg Luc-Akt-PH and 0.3 µg pYFP-
Mem cDNAs per 10.3 mm dish and transferred to a 96 well
plate 24 h before BRET experiments. BRET experiments were
performed as described previously [26,27]. Results were
expressed in milliBRET units as previously described [28,29].
Luciferase assay
The ESR1-Luc reporter gene (firefly luciferase coding
sequence under the control of the P1 promoter of ESR1 gene
[30], kindly provided by Dr. M. LE ROMANCER-CHERIFI) was
used. Cells were seeded in 12-well-plates and transfected 24 h
later with 1 µg of ESR1-Luc plasmid combined with 2 ng of a
Renilla luciferase cDNA to normalize for transfection efficiency.
After treatment, cells were lysed and luciferase activities were
measured with a Centro LB 910 luminometer (Berthold) using
the DUAL Luciferase Assay kit (Promega).
Western-blotting
MCF-7 cells were lysed with buffer containing 50 mM Tris–
HCl (pH 8), 137 mM NaCl, 10% (v/v) glycerol, 1% (v/v) NP40,
50 mM NaF, 10 mM di-sodium β-glycerophosphate, 1 mM Na
3VO4, 1 mM streptozotocin and protease inhibitors (1µg/ml
pepstatin, antipain, leupeptin, aprotinin and AEBSF). Proteins
were then analysed by SDS-PAGE followed by western-blotting
[31].
RNA extraction, Reverse Transcription and qPCR
After treatment, cells cultured in 6-well-plate were lysed
directly in Trizol reagent (Life Technologies) and RNA were
isolated and reverse transcribed as previously described [32].
Levels of the cDNA of interest were measured by qPCR using
LightCycler FastStart DNA Master SYBR Green 1 kit. To
ensure absence of genomic DNA contamination, RNA samples
were treated in parallel without Reverse Transcriptase and
controlled for absence of amplification by qPCR. The
sequences of the primers used in these experiments are:
ESR1: Forward, GCATTCTACAGGCCAAATTCAG, Reverse,
GTCGTTATGTCCTTG AATACTTC; p21: Forward,
TGTACCCTTGTGCCTCGCTCAG; Reverse, TGTA
CCCTTGTGCCTCGCTCAG; EGR1: Forward,
GCACCTGACCGCAGAGTCTT, Reverse,
AGTGGTTTGGCTGGGGTAACT; Cyclophilin A: Forward,
GGTGACTTC ACACGCCATAATG, Reverse,
ACAAGATGCCAGGACCCGTAT. Gene expression was
normalized using cyclophilin A mRNA level as a reference.
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Statistical analysis
Statistical analyses were performed with Prism software
(GraphPad) using either a t test or ANOVA followed by post-
test as indicated in figure legends.
Results
O-GlcNAcylation-inducing treatments protect MCF-7
cells from 4OH-Tamoxifen-induced cell death
We used the Uptiblue, which monitors the cellular growth
within the same well, to evaluate the effect of different
treatments on MCF-7 cells [24]. Cells were treated with
PUGNAc (inhibitor of OGA) and glucosamine (bypasses the
GFAT rate limiting step) in absence or presence of 4-OH-
Tamoxifen. Treatment with PUGNAc and glucosamine (GlcN)
markedly increase O-GlcNAcylation of proteins in MCF-7 cells,
both in the absence and presence of 4-OH-Tamoxifen (Figure
S1).
Figure 2A shows that treatment with PUGNAc and/or GlcN
had no significant effect on cell growth. 4-OH-Tamoxifen
markedly reduced the growth of the cell population after 24 h of
culture. Interestingly, the effect of 4-OH-Tamoxifen was
partially reversed by the presence of either PUGNAc or GlcN,
and completely reversed when adding both agents together.
Similar results were observed after 48 h of culture with the
different agents (Figure 2B). These results suggest that
treatment with PUGNAc and GlcN protects MCF-7 cells form 4-
OH-Tamoxifen-induced cell death.
We then studied more specifically the effects of 24h
treatments on apoptosis using FACS analysis, after labelling
the cells with Annexin V-FITC and propidium iodide. In
absence of Tamoxifen, PUGNAc and GlcN had no significant
effect on cell apoptosis. Tamoxifen induced a 2-fold increase in
apoptosis, which was prevented by the presence of PUGNAc +
GlcN (Figure 2C).
To confirm the involvement of O-GlcNAc modifications in
protection from 4OH-tamoxifen-induced cell death, we used
siRNA to study the effect of inhibiting OGT expression on
apoptosis. As shown in Figure 3A, the expression of OGT was
inhibited in siOGT-transfected cells compared to control
(siNeg-transfected) cells, which in turn resulted in a decrease
in the level of O-GlcNAcylated proteins. Figure 3B shows that
inhibition of OGT expression increased tamoxifen-induced cell
death. Altogether, these results indicate that increased O-
GlcNAcylation protects MCF-7 cells from tamoxifen-induced
apoptosis, whereas inhibition of OGT sensitizes these cells to
the effects of tamoxifen.
O-GlcNAc-inducing treatments stimulate the PI-3
kinase/Akt pathway in MCF-7 cells
The PI-3 kinase/Akt pathway is known as a major anti-
apoptotic pathway in MCF-7 cells. To determine whether O-
GlcNAcylation-inducing treatments may affect this pathway, we
used our previously developed BRET-based assay to monitor
PIP3 production in intact living cells [25]. In this assay, cells are
co-transfected with cDNA coding for the PH domain of Akt
fused to Renilla Luciferase and YFP targeted to the plasma
membrane (Figure 4A). Cells were incubated with PUGNAc,
GlcN or both for 6h prior to BRET assay. Whereas treatment
with PUGNAc or GlcN alone had only modest effects on PIP3
production, a significant increase was observed when both
agents were added together (Figure 4B, C). In agreement with
this result, we observed that PUGNAc+GlcN treatment for 6 or
24h resulted in increased Akt phosphorylation in MCF-7 cells
(Figure 4D).
Protection of 4-OH-Tamoxifen-induced cell death by O-
GlcNAc-inducing treatments is independent of PI-3
kinase/Akt pathway
To determine whether PUGNAc+GlcN protective effects
against 4-OH-Tamoxifen-induced cell death were mediated by
their stimulatory effect on PI-3 kinase/Akt pathway, we
evaluated the effects of these treatments in presence of
LY294002, a PI-3 kinase inhibitor. We observed that
LY294002, which markedly inhibited Akt phosphorylation in
these conditions (Figure S2), did not impair PUGNAc+GlcN
rescue from 4-OH-Tamoxifen-induced cell death (Figure 5).
This result strongly suggested that the protective effect of O-
GlcNAcylation-inducing treatment is not mediated by the PI-3
kinase pathway.
Independence of the PI-3kinase pathway was confirmed by
evaluating the effect of IGF-1. As previously demonstrated [25],
IGF-1 markedly stimulated PIP3 production in these cells
(Figure 6A, B). Although IGF-1 had a much higher effect on
PIP3 production than PUGNAc+GlcN (Figure 6B), no significant
rescue from 4-OH-Tamoxifen-induced cell death was observed
(Figure 6C). In contrast, the protective effect of PUGNAc+GlcN
against tamoxifen induced cell death was still observed, and
was similar in absence and presence of IGF1.
Therefore, although these experiments reveal a novel and
highly interesting effect of O-GlcNAcylation-inducing treatments
on the PI-3 kinase/Akt pathway, protection against 4-OH-
Tamoxifen-induced cell death by these treatments appears to
be independent of this pathway.
ERα expression is inhibited by increased O-
GlcNAcylation in MCF-7 cells
Tamoxifen effects on breast cancer are largely mediated by
its antagonistic action against the estrogen receptor. A number
of evidences indicate that the breast cancer cell sensitivity to
tamoxifen depends on the expression level of the estrogen
receptor ERα [33,34]. Low expression level of ESR1 gene,
which codes for ERα, is an important determinant of tamoxifen
resistance in ER-positive breast tumors [35]. We hypothesised
that treatment with O-GlcNAcylation-inducing agents may
reduce 4-OH-Tamoxifen-induced cell death through inhibition
of ERα. Therefore, we evaluated the effect of PUGNAc+GlcN
on the expression of ERα in MCF-7 cells by RT-qPCR and
western-blotting. As shown in Figure 7, 24h treatment of
MCF-7 cells with PUGNAc+GlcN markedly reduced ERα
expression at both the mRNA and protein levels. Time-course
experiments (Figure 8) indicated that inhibition of ERα
expression could already be detected at the mRNA level 6h
after of treatment with PUGNAc+GlcN (Figure 8A), and was
readily detected at the protein level after 12 h of treatment
(Figure 8B).
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Figure 2.  O-GlcNAcylation-inducing treatments protect from tamoxifen-induced cell death.  MCF-7 cells were cultured in
presence of 1% FBS during 24 h (A) or 48 h (B), in the absence or presence PUGNAc (100 µM), Glucosamine (GlcN, 5 mM) and 4-
OH-tamoxifen (10 µM). The cell population growth in each well was evaluated using an Uptiblue-based-assay as the ratio of final
fluorescence over the initial one (broken line) in the same well. Each determination corresponds to measurements performed in
triplicate wells. Results are the mean±SEM of at least 7 independent experiments. Statistical analysis was performed using ANOVA
followed by Dunnet’s post-test. *, P< 0.05; **, P< 0.01 when compared to untreated control; NS, not significant. (C) MCF-7 cells
were cultured in presence of 1% FBS during 24 h, in the absence or presence of PUGNAc+GlcN and 4-OH-tamoxifen (10 µM) and
then analysed by FACS after Annexin V-FITC/Propidium Iodide staining. Statistical analysis was performed using ANOVA followed
by Tukey’s post-test *, P< 0.05; **, P< 0.01. Results correspond to the mean±SEM of at least 4 independent experiments.
doi: 10.1371/journal.pone.0069150.g002
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Figure 3.  Inhibition of OGT expression sensitizes MCF-7 cells to tamoxifen-induced apoptosis.  MCF-7 cells were
transfected with control (siNEG) or anti-OGT siRNA (siOGT, sequence: TGGCATCGACCTCAAAGCA). (A) OGT protein expression
and global O-GlcNAc levels were analysed 48h later by western-blot. (B) 48h after transfection with siRNA, cells were cultured for
24 hours in absence or presence of 4-OH-tamoxifen (10 µM) and then analysed by FACS after Annexin V-FITC/Propiduim Iodide
staining. Statistical analysis was performed using ANOVA followed by Tukey’s post-test *, P< 0.05. Results correspond to the mean
±SEM of 5 independent experiments.
doi: 10.1371/journal.pone.0069150.g003
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Figure 4.  O-GlcNAc-inducing treatments stimulate the PI-3 kinase/Akt pathway in MCF-7 cells.  (A) Principle of the BRET
assay to measure PIP3 production in living cells. Activation of PI-3 kinase induces the phosphorylation of phosphatidyl-inositol 2
phosphate (PIP2) into phosphatidyl-inositol 3 phosphate (PIP3) and subsequent recruitment of Akt to the plasma membrane through
its pleckstrin homology (PH) domain. To monitor the production of PIP3 induced by receptor activation, cells are co-transfected with
cDNAs coding for the PH domain of Akt fused to luciferase (Luc-Akt-PH) and YFP fused to a membrane localization sequence. (B)
48 h after transfection, cells were pre-incubated for 6 h in presence of PUGNAc, GlcN or both. Cells were incubated for 10 min with
coelenterazine, then light acquisition at 480 nm and 530 nm started. A typical experiment is shown. (C) PUGNAc and GlcNAc-
induced BRET (BRET above basal at the plateau). Results are the means ± S.E.M. of 4 to 8 independent experiments. Statistical
analysis was performed using ANOVA followed by Dunnet’s post-test. **, P< 0.01 when compared to untreated control. (D) Effect of
O-GlcNAcylation-inducing treatment on Akt phosphorylation. MCF-7 cells were incubated in the absence or presence of PUGNAc
+GlcN for 6h or 24 h and lysed. The phosphorylation of Akt was evaluated by western-blot using anti-phospho-S473-Akt antibody.
doi: 10.1371/journal.pone.0069150.g004
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To determine whether O-GlcNAcylation-inducing treatments
affect ERα expression through a transcriptional mechanism, we
transfected MCF-7 cells with a reporter gene constituting of the
firefly luciferase coding sequence under the control of ESR1
promoter. Twelve hours after transfection, cells were treated
with PUGNAc+GlcN for 24h, and then lysed for luciferase
activity measurements. As shown in Figure 9A, PUGNAc+GlcN
treatment markedly reduced the expression of ESR1 promoter
reporter gene. To further confirm the role of protein O-
GlcNAcylation in the regulation of ESR1 promoter, a luciferase
reporter gene assay was performed after over-expression of
OGT. Transfection with OGT cDNA increased OGT expression
and protein O-GlcNAcylation in MCF-7 cells (Figure S3). Figure
9B shows that the ESR1-Luc reporter gene expression was
significantly reduced when OGT cDNA was co-transfected with
the reporter gene. This inhibitory effect was accentuated by
glucosamine, which provides UDP-GlcNAc to OGT. We also
evaluated the effect of PUGNAc+GlcN on ERα expression in
presence of tamoxifen. The inhibitory effect of PUGNAc+GlcN
on ESR1 promoter activity was still observed when cells were
cultured in presence of tamoxifen (Figure S4A). At the mRNA
level, tamoxifen alone tended to decrease the expression of
ERα As a consequence, in presence of tamoxifen, although
PUGNAc+GlcN further decreased ERα mRNA level, the
difference between cells treated or not with PUGNAc+GlcN
was not significant. However, it should be noted that whereas
the decrease in mRNA level induced by tamoxifen alone was
not significant when compared to untreated control cells, this
effect became significant in presence of PUGNAc+GlcN,
indicating that PUGNAc+GlcN favours inhibition of ERα mRNA
expression, even in presence of tamoxifen (Figure S4B). At the
protein level, tamoxifen increased ERα, in agreement with
previous data showing that tamoxifen increase ERα protein
expression through a post-transcriptional mechanism [36],
presumably by protecting ERα from proteasomal degradation
[37,38]. However, despite tamoxifen-induced increase in ERα
protein level, PUGNAc+GlcN treatment was still capable of
significantly decreasing ERα protein expression (Figure S4C
and D). This suggests that in presence of tamoxifen, under
PUGNAc+GlcN conditions, less ERα protein is available to
transmit tamoxifen effects compared to the minus PUGNAc
+GlcN condition.
To determine whether O-GlcNAc-induced inhibition of ERα
expression was associated with an inhibition of tamoxifen effect
on gene expression, we studied the mRNA expression of
genes coding for p21 and Egr1 by RT-qPCR. p21 and Egr1
negatively regulate cell proliferation and were previously shown
to be activated by tamoxifen in MCF-7 cells [39,40]. We
Figure 5.  Protection of MCF-7 cells from 4-OH-tamoxifen-induced cell death is not abrogated by inhibition of the PI-3
kinase/Akt pathway.  MCF-7 cells were cultured in presence of 1% FBS during 24 hours in the absence or presence PUGNAc (100
μM), Glucosamine (GlcN, 5 mM), 4-OH-tamoxifen (10 μM) and either DMSO (vehicle) or the PI-3 kinase inhibitor LY294002 (LY) at
a concentration of 10 or 20 µM. The growth of the cell population in each well was evaluated using Uptiblue-based-assay as the
ratio of final fluorescence over the initial one (broken line) in the same well. Each determination corresponds to measurements
performed in triplicate wells. Results are the mean±SEM of 3 independent experiments. Statistical analysis was performed using
ANOVA followed by Dunnet’s post-test. *, P< 0.05 when compared to corresponding untreated control; NS, not significant.
doi: 10.1371/journal.pone.0069150.g005
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Figure 6.  IGF-1 treatment does not protect MCF-7 cells from 4OH-tamoxifen-induced cell death.  (A) MCF-7 cells were co-
transfected with cDNAs coding for the PH domain of Akt fused to luciferase (Luc-Akt-PH) and YFP fused to a membrane localization
sequence. 48 h after transfection, cells were pre-incubated for 6 h in the absence or presence of PUGNAc+GlcN. Cells were
incubated for 10 min with coelenterazine and then stimulated with 100 nM IGF-1. Light acquisition at 480 nm and 530 nm started
immediately after IGF-1 addition. A typical experiment is shown. (B) PUGNAc+GlcNAc and IGF-1-induced BRET (BRET above
basal at the plateau). Results are the means ± S.E.M. of at least 5 independent experiments. Statistical analysis was performed
using ANOVA followed by Tukey’s post-test. *, P< 0.05; **, P< 0.01; NS, not significant. (C) MCF-7 cells were cultured in presence
of 1% FBS during 24 h in the absence or presence PUGNAc (100 µM), Glucosamine (GlcN, 5 mM), 4-OH-tamoxifen (10 µM) and
IGF-1 (100 nM). Cell population growth in each well was evaluated using an Uptiblue-based-assay as the ratio of final fluorescence
over the initial one (broken line) in the same well. Each determination corresponds to measurements performed in triplicate wells.
Results are the mean±SEM of 5 independent experiments. Statistical analysis was performed using ANOVA followed by Tukey’s
post-test. *, P< 0.05; **, P< 0.01; NS, not significant.
doi: 10.1371/journal.pone.0069150.g006
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observed PUGNAc+GlcN reduced the stimulatory effect of
tamoxifen on the expression of these genes (Figure 10).
Altogether, these data suggest that O-GlcNAcylation-
inducing treatments inhibited ERα expression, and this
Figure 7.  Inhibition of ERα expression level by O-GlcNAcylation-inducing treatments.  Cells were cultured for 24 h in the
absence or presence of PUGNAc+GlcN. (A) RNA were extracted and the expression of ERα mRNA was evaluated by RT-qPCR.
(B) Cells were lysed and the expression of ERα protein was analysed by western-blot. GAPDH expression level was used as
loading control. (C) ERα/GAPDH signals quantified by densitometric analysis of the autoradiograms of western-blots from 6
independent experiments. Statistical analysis was performed using unpaired t test. *, P< 0.05; ***, P< 0.001.
doi: 10.1371/journal.pone.0069150.g007
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Figure 8.  Time-course of inhibition of ERα expression by O-GlcNAcylation-inducing treatments.  Cells were cultured in
absence or presence of PUGNAc+GlcN for 6, 12, 24 and 36 h. (A) RNA was extracted and the expression of ERα mRNA was
evaluated by RT-qPCR. Statistical analysis was performed using unpaired t test. *, P< 0.05; **, P< 0.01; ***, P< 0.001. Results
correspond to the mean±SEM of at least 4 independent experiments. (B) Cells were lysed at the indicated times and the expression
of ERα protein was analysed by western-blot. GAPDH expression level was used as loading control. The effect of PUGNAc+GlcN
treatment on O-GlcNAcylation of proteins was controlled using anti-O-GlcNAc antibody. Results are representative of at least 3
independent experiments.
doi: 10.1371/journal.pone.0069150.g008
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Figure 9.  Inhibition of ESR1 promoter activity by O-GlcNAcylation-inducing treatments.  (A) MCF-7 cells were co-transfected
with ESR1 promoter-Firefly luciferase reporter gene (ESR1-luc) and Renilla luciferase cDNAs. 12 h after transfection, cells were
treated with PUGNAc+GlcN for 24 h and then lysed for determination of Firefly and Renilla luciferase activities. Each determination
was performed in triplicate. Results are mean±SEM of three independent experiments. Statistical analysis was performed using
unpaired t test ; *, P< 0.05. (B) Cells were transfected as in A, but the ESR1-Luc and Renilla luciferase plasmids were co-
transfected with either pcDNA3.1 control plasmid or OGT expression vector. Cells were then treated with GlcN for 24 h and then
lysed for determination of Firefly and Renilla luciferase activities. Each determination was performed in triplicate. Statistical analysis
was performed using ANOVA followed by Tukey’s post-test **, P< 0.01; ***, P< 0.001. Results correspond to the mean±SEM of 4
independent experiments.
doi: 10.1371/journal.pone.0069150.g009
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Figure 10.  PUGNAc+GlcNAc treatment inhibited the effect of 4-OH-tamoxifen on p21 and Egr1 gene expression.  Cells were
cultured for 24h in absence or presence of 4-OH tamoxifen or in presence of 4-OH-Tamoxifen and PUGNAc+GlcN. (A) RNA were
extracted and the level of p21 and Egr1 mRNA was evaluated by RT-qPCR and normalised using Cyclophilin A expression levels.
Results are the mean ±SEM of 3 independent experiments. Statistical analysis was performed by ANOVA followed by Dunnet’s
post-test. *, P< 0.05; **, P< 0.01 when compared to untreated control.
doi: 10.1371/journal.pone.0069150.g010
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inhibition was associated with a reduction of tamoxifen effect
on key genes involved in regulation of cell proliferation.
Discussion
O-GlcNAcylation has been implicated as an important
determinant in cancer cell growth and migration [16–21].
However, its role in the sensitivity to anti-cancer therapy was
not investigated in these studies. In the present work, we
demonstrate that increasing O-GlcNAcylation results in
important protective effects against tamoxifen-induced cell
death in the MCF-7 cell line.
In MCF-7 cells, increased activity of the PI-3 kinase/Akt
pathway has been previously shown to participate in resistance
to various chemotherapeutic agents, including tamoxifen [41].
To evaluate the potential involvement of this pathway in the
protective effects of O-GlcNAc-inducing treatments, we used
our previously developed BRET-based assay to assess PIP3
level in living cells. We observed that PUGNAc+GlcN treatment
significantly increased PIP3 production in MCF-7 cells and was
associated with an increase in Akt phosphorylation.
Interestingly, recent work also suggested a link between PI-3
kinase activity and OGT expression level in cancer cells [42].
The mechanism by which O-GlcNAc increases PI-3K/Akt
pathway activity in MCF-7 cells remains elusive. Whereas O-
GlcNAcylation of the p85 subunit [43] of PI-3K has been
previously described, its consequences on its activity have not
been studied. Moreover, whereas O-GlcNAcylation of Akt has
been largely described [5,9,44,45], this modification is rather
associated with a decrease in its phosphorylation. PIP3 level at
the plasma membrane depends on the balance between PIP2
phosphorylation by PI-3 kinase activity and PIP3
dephosphorylation by the lipid-phosphatase PTEN. Clearly, the
effect of O-GlcNAc treatment on PI-3 kinase and PTEN
expression and/or activity in MCF-7 cells deserves further
investigations.
Whatever the mechanism involved in O-GlcNAc-induced
increase in PI-3-kinase/Akt pathway in these cells, it does not
appear to play a significant role in the protective effect of O-
GlcNAc against tamoxifen-induced cell death. Indeed,
pharmacological inhibition of the PI-3 kinase/Akt pathway using
LY294002 did not impair the protective effects of PUGNAc
+GlcN treatments on 4-OH-tamoxifen induced cell death.
Moreover, using IGF1, we demonstrated that activation of PI-3
kinase is not sufficient to rescue MCF-7 cells from tamoxifen
effects, whereas PUGNAc+GlcNAc treatment was still efficient
under these conditions. This prompted us to investigate
whether O-GlcNAcylation, rather than acting through a general
anti-apoptotic signalling pathway, may affect a protein more
specifically involved in tamoxifen action.
Tamoxifen exerts its effects on estrogen-receptor positive
cells by binding to ERα. ERα expression is both necessary and
sufficient to predict the responsiveness to anti-estrogen in a
high proportion of breast tumors, and low expression level is
generally associated with a poor prognosis [33–35,46,47].
We observed that O-GlcNAcylation-inducing treatment
results in inhibition of ERα expression, suggesting a potential
mechanism for decreased tamoxifen effect. Inhibition of ERα
mRNA expression could be detected after only 6 h of
treatment, and luciferase reporter gene assay indicated that
PUGNAc+GlcN treatments inhibit the activity of the ESR1
promoter reporter gene. This suggests that the inhibition of
ERα expression occurred at least in part through a
transcriptional repression mechanism. This inhibition appeared
to be independent of the effect of O-GlcNAc on PI-3 kinase/Akt
pathway, because treatment of MCF-7 cells with LY294002 did
not impair inhibition of ERα expression by PUGNAc+GlcN
treatment (data not shown).
Positive and negative regulation of gene expression by post-
translational modification of transcription factors has been
largely documented [8,48,49]. Interestingly, Sp1, one the first
transcription factors identified to be modified by O-
GlcNAcylation [50], is known to bind to and positively regulate
the ESR1 promoter activity [51]. Indeed, Sp1 appears to
participate in a transcription complex (comprised of USF1 and
ERα itself) that regulates the expression of ESR1. O-
GlcNAcylation of Sp1 has been largely associated with
decreased transcriptional activity on various promoters,
generally through dissociation of its interaction with
transcription factors or co-activators [52–58]. Therefore, is
would be of interest to determine whether the effect of
PUGNAc+GlcN in MCF-7 cells is associated with dissociation
of this complex.
Expression of the ERα, a good prognostic factor in breast
cancer, is associated with higher levels of p21 proteins.
Tamoxifen is known to modulate the expression of genes
involved in cell proliferation and cell death. Increased
expression of the cell cycle regulator p21WAF1/CIP1 is believed to
play a role in cell cycle arrest upon treatment with tamoxifen
and other anti-estrogen drugs [39,59]. Moreover, down-
regulation of p21WAF1/CIP1 using antisense RNA abrogates anti-
estrogen-mediated cell cycle arrest in MCF-7 cells [39].
Similarly, Egr1 is deleted in ER-negative human breast
carcinoma, which is suggested to contribute to the poor
prognosis of ER-negative versus ER-positive breast
carcinomas [60]. Decreased Egr1 expression in human, mouse
and rat mammary cells and tissues correlated with tumor
formation, and tamoxifen treatment was shown to restore its
expression in rat mammary tumors [40]. Moreover, in the ER-
positive breast cancer cells MDA-MB-361, tamoxifen-induced
increase in Egr1 expression resulted in activation p21WAF1/CIP1
promoter and increased transcription of p21WAF1/CIP1 gene,
providing a link between Egr1 transcriptional activity, p21
expression and tamoxifen-induced cell cycle arrest [61]. Our
results indicated that O-GlcNAcylation-inducing treatment
reduced the stimulatory effect of tamoxifen on Egr1 and p21
expression, providing a potential mechanism for the protective
effects of O-GlcNAc on tamoxifen-induced inhibition of cell
growth. However, the effect tamoxifen on Egr1 and p21 gene
expression is only partially inhibited by O-GlcNAc-inducing
treatments. This may in part reflect the fact that O-GlcNAc-
induced inhibition of ERα expression is only partial (Figures 7
and 8), and the remaining receptors could be responsible for
the residual effect of tamoxifen.
In summary, we have observed that increased O-
GlcNAcylation in MCF-7 cells have inhibitory effects on
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tamoxifen induced cell death. Although O-GlcNAc-inducing
treatments stimulate the PI-3 kinase/Akt pathway through an
unknown mechanism, protection from tamoxifen-induced cell
death appear to be independent of this pathway. Moreover, we
observed that increased O-GlcNAcylation reduces the
expression of ERα, one of the main determinants of tamoxifen
sensitivity. However, several laboratories have shown that
tamoxifen can have ERα-independent anti-proliferative and
pro-apotptotic effects [62–64]. In the present study, it cannot be
ruled out that O-GlcNAcylation may also protect MCF-7 cells
from ERα-independent effects of tamoxifen. Therefore,
additional work will be required to determine to what extent
reduction in ERα expression is responsible for reduced
tamoxifen effect upon O-GlcNAcylation-inducing treatment.
Overall, although no firm conclusion can be drawn concerning
the mechanism(s) by which O-GlcNcylation protects MCF-7
cells from tamoxifen effects, our results suggest that targeting
the O-GlcNAc pathway might be an interesting therapeutic
approach for sensitisation of anti-estrogen resistant breast
tumors.
Supporting Information
Figure S1.  Effect of PUGNAc and Glucosamine on O-
GlcNAc level in MCF-7 cells treated or not with 4-OH-
tamoxifen.  MCF-7 cells cultured in absence (Ct) or presence
of PUGNAc (P), glucosamine (G) or PUGNAc+glucosamine
(PG), were treated or not with of 4-OH-tamoxifen (10 µM). After
24 h of treatment, cells were lysed and protein O-
GlcNAcylation level was evaluated by western-blotting. GAPDH
expression level was used as a loading control.
(TIF)
Figure S2.  Effect of LY294002 on Akt phosphorylation in
MCF-7 cells.  MCF-7 cells treated with 10 or 20 µM LY294002
(LY) or vehicle (DMSO) were cultured during 24 h in absence
or presence PUGNAc+GlcN and/or tamoxifen. Cells were lysed
and Akt phosphorylation level was evaluated by western-
blotting using anti-phospho-S473-Akt antibody. As a control for
specificity of PI-3 kinase inhibition, Erk phosphorylation
(evaluated using anti-phospho-Erk1/2 antibody) was shown to
be unaffected by LY294002 treatment in the same
experiments.
(TIF)
Figure S3.  Effect of OGT transfection on OGT expression
and O-GlcNAcylation level in MCF-7 cells.  MCF-7 cells
were transfected with either pcDNA3 or OGT cDNA. 48 h after
transfection, cells were lysed. OGT expression and O-
GlcNAcylation level of proteins were evaluated by western-
blotting. GAPDH expression level was used as a loading
control.
(TIF)
Figure S4.  Effect of PUGNAc+GlcN on ESR1 promoter and
ERα expression in presence of 4-OH-tamoxifen.  (A) MCF-7
cells were co-transfected with ESR1 promoter-Firefly luciferase
reporter gene (ESR1-luc) and Renilla luciferase cDNAs. 12
hours after transfection, cells were treated with PUGNAc+GlcN
in the absence or presence of 4-OH-tamoxifen for 24 h and
then lysed for determination of Firefly and Renilla luciferase
activities. Each determination was performed in triplicate.
Results are mean±SEM of three independent experiments.
Statistical analysis was performed using ANOVA followed by
Tukey’s post-test. *, P< 0.05; **, P< 0.01; NS, not significant
(B) Cells were cultured for 24 h in the absence or presence of
PUGNAc+GlcN and 4-OH-tamoxifen. RNA was then extracted
and the expression of ERα mRNA was evaluated by RT-qPCR.
Results are the mean±SEM of 4 independent experiments.
Statistical analysis was performed using ANOVA followed by
Tukey’s post-test. *, P< 0.05; **, P< 0.01; NS, not significant.
(C) Cells were lysed and the expression of ERα protein was
analysed by western-blot. GAPDH expression level was used
as loading control. (D) ERα/GAPDH signals quantified by
densitometric analysis of the autoradiograms of western-blots
from 6 independent experiments. Statistical analysis was
performed using ANOVA followed by Tukey’s post-test. ***, P<
0.001.
(TIF)
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